Ilixadencel (allogeneic dendritic cells) : A Promising Treatment For GIST (advanced gastrointestinal stromal tumor)

advanced gastrointestinal stromal tumor

Advanced gastrointestinal stromal tumor

CONTACT US

Introduction

This Phase I trial was carried out to evaluate safety and efficacy of intratumorally administered inflammatory allogeneic dendritic cells (ilixadencel) in advanced gastrointestinal stromal tumors. Ilixadencel DCT Dendritic Cell Therapy is a promising treatment for GIST patients who have developed resistance to TKI.

Results

Encouraging radiological tumor responses were detected in 33% of treated patients, supporting further investigation into DCT Dendritic Cell Therapy as a potential alternative to conventional therapies. 

Conclusion

Ilixadencel (allogeneic dendritic cells) treatment presented an acceptable safety profile among advanced GIST patients who developed resistance to TKI. Encouraging radiological tumor responses were detected in 33% of treated patients, supporting further investigation.

DCT Dendritic Cell Therapy may even be combined with TKI treatment to provide additional benefit for GIST patients.

Article Reference link: click here

Scientific article publishing date : 13/6/2020

Immucura identifier : BSC21_004En

ALL SCIENTIFIC PAPERS
CONTACT US